Open AccessDexamethasone and Nutraceutical Therapy Can Reduce the Myalgia Due to COVID-19 "&#".ord($0).";""&#".ord($0).";""&#".ord($0).";" a Systemic Review of the Active Substances that Can Reduce the Expression of Interlukin-6
Author(s) -
Umberto Ripani,
Michele Bisaccia,
Luigi Meccariello
Publication year - 2022
Publication title -
medicinski arhiv
Language(s) - English
Resource type - Journals
eISSN - 1986-5961
pISSN - 0350-199X
DOI - 10.5455/medarh.2022.76.66-71
Subject(s) - myalgia , medicine , dexamethasone , immune system , cytokine storm , tumor necrosis factor alpha , inflammation , immunology , pharmacology , covid-19 , disease , infectious disease (medical specialty)
Myalgia reflects generalized inflammation and cytokine response and can be the onset symptom of 36% of patients with COVID-19. Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF- α) levels in plasma and upper respiratory secretions directly correlate with the magnitude of viral replication, fever, and respiratory and systemic symptoms, including musculoskeletal clinical manifestations.